Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study

Fig. 3

Sensitivity analyses of the hazard ratio for incident AF for the paired study cohorts treated with SGTL2i versus DPP4i, SGLT2i versus GLP-1RA, and GLP-1RA versus DPP4i after PSM. The sensitivity analyses showed the results were robust, and consistent with the main analysis. The use of SGLT2i was still associated with a lower risk of new-onset AF compared with either DPP4i or GLP-1RA after PSM, using death as a competing risk factor consistent with the main analysis. Specifically, we identified incident AF using either hospitalized diagnosed AF; AF with treatment using anti-arrhythmic drugs, cardioversion, or catheter ablation; or only patients without previous drug exposure, underlying ESKD, or concomitant use of insulin, the results remained consistent with the main analyses. There were no differences in the risk of incident AF with consequent use of oral anticoagulant treatment for three paired study groups

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840